Cannabis Law Report

MAY 6, 2022

On May 4, 2022, the FDA issued five warning letters to companies for selling products containing hemp-derived Delta-8 THC. Previously, the agency issued and updated a consumer advisory outlining consumer safety concerns relating to Delta-8 products. “[D]elta-8-THC was administered to eight children being treated for hematologic cancers.

Hemp 52

Hemp Food Safety THC 52

Cannabis Law Report

OCTOBER 22, 2021

To date, more than 50 novel compounds have been evaluated through collaborations with experienced contract research organizations for pharmacokinetic/pharmacodynamic profile, metabolic stability, receptor binding, and safety in order to identify preferred candidates for further development.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time. Dr. Nick Allen, co-founder and CEO of Ksana Health, commented: “Psychedelic treatments are offering exciting new approaches to recovery from mental disorders.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Veriheal

JUNE 30, 2023

Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

APRIL 14, 2022

Similar issues arise under state and federal employee safety and worker Right-to-Know laws, as employees must be educated on the chemicals present and proper handling and risk management procedures. Since growing cannabis has not always been legal, growers did not always choose pesticides that were “approvable” by EPA. Next Steps.

Environment 52

Environment Agriculture Compliance Compliance 52

Veriheal

DECEMBER 23, 2022

Dr. Maxwell’s team also collected data contained in samples sourced from California. After a close analysis of the data, the team determined that an absence of consistent federal guidelines regarding marijuana contaminants ultimately increases the risk of consumers developing health issues. 74 solvents. 21 microbes.

Research and Development 92

Research and Development Agriculture Data Extraction 92

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Brian Schatz & Cory Booker to Acting Director Tabak and Commissioner Califf (May 11, 2022), [link]. [2] Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 9, 2021

I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. The study involved 100 treatment-resistant patients and were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

NOVEMBER 26, 2021

Topline results are expected in Q1 2022. We expect to commence enrollment in our pivotal Phase III liver cancer and Phase IIb NASH studies, as we look forward to topline results from our Phase III in psoriasis in the first quarter of 2022. dollars in thousands (except for share and per share data). . . Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

The Cannigma

JANUARY 13, 2023

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. Daily cannabis consumption was an effective treatment for 85% of participants. headaches per month.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours). Psilocybin Pharmacology, Neuroscience, and Clinical Research (12 Hours).

Law 52

Law Programs Therapy Education 52

Freedom Leaf

OCTOBER 15, 2018

Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. On July 23, the World Health Organization’s Expert Committee on Drug Dependence stated that “no public health problems have been associated with CBD use” and that “CBD has been found to be generally well tolerated with a good safety profile.”

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

NOVEMBER 29, 2021

As we approach the 2022 legislative session and the elections next November, it is important for lawmakers of all political persuasions to recognize that advocating for marijuana policy reforms is a political opportunity, not a political liability,” NORML’s Paul Armentano said. The law will take effect in January 2022. California.

Legislation 98

Legislation Patients Retail Access 98

Cannabis Law Report

AUGUST 23, 2021

Analysts predict that pet-and-animal product sales are among the fastest-growing sectors in the CBD market with estimated sales reaching $125 million by 2022. He added that significant data is still needed to inform policy regarding use of consumer cannabis products. WRITTEN BY: Womble Bond Dickinson. Heather Hatcher, Ph.D.

Pets 105

Pets Hemp CBD Food 105

Veriheal

JANUARY 5, 2022

Despite the restrictions on research as a result of the Schedule I classification of cannabis, researchers have made many remarkable strides in proving the efficacy and safety of cannabis on the aforementioned conditions. . While Biden is receiving a lot of heat as a result of his inaction, many feel it is deserved.

Legislation 52

Legislation Cannabis Therapy Access 52

Cannabis Law Report

MAY 19, 2022

FDA states it has serious safety concerns with delta-8 THC. FDA states it has received 104 reports of adverse events in patients who consumed delta-8 THC products between December 1, 2020 and February 28, 2022. FDA considers delta-8 THC to pose serious health and safety risks. FDA Warning Letters. meat, milk, and eggs).

THC 52

THC CBD Food Pets 52

Cannabis Law Report

AUGUST 27, 2021

The Rules will be effective until at least August 19, 2022. The Rules aim to promote social equity, safety and easy access to the cannabis marketplace while keeping local municipalities in control of how they want cannabis businesses to operate in their jurisdiction. –> Scroll to see full table data. Submission Fee.

Cultivation 105

Cultivation Conditions Business Cannabis 105

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa. and Torsten Falk, Ph.D.,

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

MAY 6, 2022

May 6, 2022. The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Michelle R.E.

THC 52

THC CBD Media Food 52

Cannabis Law Report

JUNE 7, 2021

Of the cannabis-related tax revenue it collects, the state distributes 40% to public schools, 15% to law enforcement, and 25% to mental health and treatment programs. Data for tax revenue from wholesale taxes has not yet been made available. Regulated sales are scheduled to begin on May 1, 2022. Arizona (pop. New Mexico (pop.

Marijuana 91

Marijuana Retail Collective Programs 91

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. At the time of FY 2020 results publication, we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

JANUARY 9, 2022

Of the cannabis-related tax revenue it collects, the state distributes 40% to public schools, 15% to law enforcement, and 25% to mental health and treatment programs. The state’s legalization law divides cannabis tax revenue into two funds, one to support public health initiatives and the other for public safety and law enforcement training.

Collective 52

Collective Policy Retail Programs 52

Cannabis Law Report

OCTOBER 29, 2021

NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability. We expect to report this data as it becomes available and after submission to the FDA.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52